Return to Today's science sparks archives

2019-02-01

Fig. 1 Clinical Pattern of Acquired Resistance.

Fig. 1 Clinical Pattern of Acquired Resistance.
  • Hu ZI, Hellmann MD, Wolchok JD, Vyas M, Shia J, Stadler ZK, Diaz LA Jr, O'Reilly EM

  • J Immunother Cancer. 2018 Nov 20;6(1):127.
Open Access button

2019-02-04

Fig. 1 Flow diagram of our general management strategies for patients with solid tumors with findings of clonal hematopoiesis (CH).

Fig. 1 Flow diagram of our general management strategies for patients with solid tumors with findings of clonal hematopoiesis (CH).
  • Bolton KL, Gillis NK, Coombs CC, Takahashi K, Zehir A, Bejar R, Garcia-Manero G, Futreal A, Jensen BC, Diaz LA Jr, Gupta D, Mantha S, Klimek V, Papaemmanuil E, Levine R, Padron E

  • J Clin Oncol. 2019 Jan 1;37(1):7-11.

2019-02-05

Fig. 2 Types of individualized local therapy for infants treated on Children's Oncology Group ARST0331 (low-risk protocol) and ARST0531 (intermediate-risk protocol).

Fig. 2 Types of individualized local therapy for infants treated on Children's Oncology Group ARST0331 (low-risk protocol) and ARST0531 (intermediate-risk protocol).
  • Bradley JA, Kayton ML, Chi YY, Hawkins DS, Tian J, Breneman J, Wolden SL, Walterhouse D, Rodeberg DA, Donaldson SS

  • Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):19-27.

2019-02-06

Fig. 1 Progressive changes in neocortical interneuron output of dividing NKX2.1+ MGE/PoA RGPs.

Fig. 1 Progressive changes in neocortical interneuron output of dividing NKX2.1+ MGE/PoA RGPs.
  • Sultan KT, Liu WA, Li ZL, Shen Z, Li Z, Zhang XJ, Dean O, Ma J, Shi SH

  • Nat Commun. 2018 Nov 2;9(1):4595.
Open Access button

2019-02-07

Fig. 1 miR-155-mediated Ago binding occurs at distinct sites in four immune cell types.

Fig. 1 miR-155-mediated Ago binding occurs at distinct sites in four immune cell types.
  • Hsin JP, Lu Y, Loeb GB, Leslie CS, Rudensky AY

  • Nat Immunol. 2018 Oct;19(10):1137-1145.

2019-02-08

Fig. 1 Core components of integrative oncology for evidence-informed patient-centered care: (A) three main therapeutic categories, and (B) components of evidence-informed practice.

Fig. 1 Core components of integrative oncology for evidence-informed patient-centered care: (A) three main therapeutic categories, and (B) components of evidence-informed practice.
  • Latte-Naor S, Mao JJ

  • J Oncol Pract. 2019 Jan;15(1):7-14.

2019-02-11

Fig. 1 Evaluation of dermoscopic features on a formalin-fixed specimen (ex vivo dermoscopy) using a smartphone attached to a dermoscope.

Fig. 1 Evaluation of dermoscopic features on a formalin-fixed specimen (ex vivo dermoscopy) using a smartphone attached to a dermoscope.
  • Yélamos O, Braun RP, Liopyris K, Wolner ZJ, Kerl K, Gerami P, Marghoob AA

  • J Am Acad Dermatol. 2019 Feb;80(2):365-377.

2019-02-12

Fig. 1 Breast white adipose tissue inflammation by BMI category (n = 91).

Fig. 1 Breast white adipose tissue inflammation by BMI category (n = 91).
  • Greenlee H, Shi Z, Hibshoosh H, Giri DD, Ahmed A, Williams S, Falcone DJ, Winston LA, Zhou XK, Hudis CA, Hershman DL, Dannenberg AJ, Iyengar NM

  • Cancer Prev Res (Phila). 2019 Jan;12(1):21-30.

2019-02-13

Fig. 1 Vascular structures and fibrosis of basal cell carcinoma on dermoscopy.

Fig. 1 Vascular structures and fibrosis of basal cell carcinoma on dermoscopy.
  • Cameron MC, Lee E, Hibler BP, Giordano CN, Barker CA, Mori S, Cordova M, Nehal KS, Rossi AM

  • J Am Acad Dermatol. 2019 Feb;80(2):321-339.

2019-02-14

Fig. 1 Cathepsin K-Cre labels periosteal mesenchymal cells.

Fig. 1 Cathepsin K-Cre labels periosteal mesenchymal cells.
  • Debnath S, Yallowitz AR, McCormick J, Lalani S, Zhang T, Xu R, Li N, Liu Y, Yang YS, Eiseman M, Shim JH, Hameed M, Healey JH, Bostrom MP, Landau DA, Greenblatt MB

  • Nature. 2018 Oct;562(7725):133-139.

2019-02-18

Figure 1 WL12 binding interface on PD-L1 overlaps with PD-1 and PD-L1 therapeutics.

Figure 1 WL12 binding interface on PD-L1 overlaps with PD-1 and PD-L1 therapeutics.
  • Kumar D, Lisok A, Dahmane E, McCoy M, Shelake S, Chatterjee S, Allaj V, Sysa-Shah P, Wharram B, Lesniak WG, Tully E, Gabrielson E, Jaffee EM, Poirier JT, Rudin CM, Gobburu JV, Pomper MG, Nimmagadda S

  • J Clin Invest. 2019 Feb 1;129(2):616-630.
Open Access button

2019-02-19

Fig. 1 CRC test exposure trajectories and failures in people who died of CRC, KPNC and KPSC 2006–2012.

Fig. 1 CRC test exposure trajectories and failures in people who died of CRC, KPNC and KPSC 2006–2012.
  • Doubeni CA, Fedewa SA, Levin TR, Jensen CD, Saia C, Zebrowski AM, Quinn VP, Rendle KA, Zauber AG, Becerra-Culqui TA, Mehta SJ, Fletcher RH, Schottinger J, Corley DA

  • Gastroenterology. 2019 Jan;156(1):63-74.e6.

2019-02-20

Fig 6. Model of Hsp90 dependence and sensitivity to Hsp90 inhibitors.

Fig 6. Model of Hsp90 dependence and sensitivity to Hsp90 inhibitors.
  • Echeverria PC, Bhattacharya K, Joshi A, Wang T, Picard D

  • PLoS One. 2019 Feb 6;14(2):e0208287.
Open Access button

2019-02-21

Figure 4. SCOT-Macrophage-KO Mice Exhibit Normal Physiological Responses to HFD.

Figure 4. SCOT-Macrophage-KO Mice Exhibit Normal Physiological Responses to HFD.
  • Puchalska P, Martin SE, Huang X, Lengfeld JE, Daniel B, Graham MJ, Han X, Nagy L, Patti GJ, Crawford PA

  • Cell Metab. 2019 Feb 5;29(2):383-398.e7

2019-02-22

Fig. 2 Maximum change in tumour size at the RP2D, according to tumour type.

Fig. 2 Maximum change in tumour size at the RP2D, according to tumour type.
  • Schram AM, Gandhi L, Mita MM, Damstrup L, Campana F, Hidalgo M, Grande E, Hyman DM, Heist RS

  • Br J Cancer. 2018 Dec;119(12):1471-1476.

2019-02-25

Acute lysolecithin lesions of the mouse corpus callosum are softer than healthy tissue.

Acute lysolecithin lesions of the mouse corpus callosum are softer than healthy tissue.
  • Urbanski MM, Brendel MB, Melendez-Vasquez CV

  • Sci Rep. 2019 Jan 30;9(1):999.
Open Access button

2019-02-26

Alderson phantom positioned underneath the beam-defining collimator of the 250 kVp x-ray machine at PXI.

Alderson phantom positioned underneath the beam-defining collimator of the 250 kVp x-ray machine at PXI.
  • Dilmanian FA, Krishnan S, McLaughlin WE, Lukaniec B, Baker JT, Ailawadi S, Hirsch KN, Cattell RF, Roy R, Helfer J, Kruger K, Spuhler K, He Y, Tailor R, Vassantachart A, Heaney DC, Zanzonico P, Gobbert MK, Graf JS, Nassimi JR, Fatemi NN, Schweitzer ME, Bangiyev L, Eley JG

  • Sci Rep. 2019 Feb 4;9(1):1198.
Open Access button

2019-02-27

Fig. 1 Structure of PARPi-FL, schematic diagram and characterization of PARPi-FL NE.

Fig. 1 Structure of PARPi-FL, schematic diagram and characterization of PARPi-FL NE.
  • Gonzales J, Kossatz S, Roberts S, Pirovano G, Brand C, Pérez-Medina C, Donabedian P, de la Cruz MJ, Mulder WJM, Reiner T

  • Bioconjug Chem. 2018 Nov 21;29(11):3776-3782.

2019-02-28

Schema for trials of extended adjuvant endocrine therapy. ABCSG, Austrian Breast Cancer Study Group.

Schema for trials of extended adjuvant endocrine therapy. ABCSG, Austrian Breast Cancer Study Group.
  • Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KA, Giordano SH, Hudis CA, Solky AJ, Stearns V, Winer EP, Griggs JJ

  • J Clin Oncol. 2019 Feb 10;37(5):423-438.

2019-03-01

Fig. 3. The thyroid gland is retracted anteriorly and medially, exposing the posterior surface of thyroid gland. This helps in the identification of the middle thyroid vein(s), which is (are) then ligated and divided.

Fig. 3. The thyroid gland is retracted anteriorly and medially, exposing the posterior surface of thyroid gland. This helps in the identification of the middle thyroid vein(s), which is (are) then ligated and divided.
  • Roman BR, Randolph GW, Kamani D

  • Endocrinol Metab Clin North Am. 2019 Mar;48(1):125-141.